Výsledky vyhledávání

Akademický článek

Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial.

Autor: Ruskin JN; Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: jruskin@mgh.harvard.edu., Camm AJ; St. George's University, London, United Kingdom., Dufton C; InCarda Therapeutics, Newark, California, USA., Woite-Silva AC; InCarda Therapeutics, Newark, California, USA., Tuininga Y; Deventer Hospital, Deventer, the Netherlands., Badings E; Deventer Hospital, Deventer, the Netherlands., De Jong JSSG; Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands., Oosterhof T; Ziekenhuis Gelderse Vallei, Ede, the Netherlands., Aksoy I; Admiraal de Ruyter Ziekenhuis, Goes, the Netherlands., Kuijper AFM; Spaarne Gasthuis, Haarlem, the Netherlands., Van Gelder IC; University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., van Dijk V; St Antonius Ziekenhuis, Nieuwegein, the Netherlands., Nuyens D; Hartcentrum Ziekenhuis Oost-Limburg, Genk, Belgium., Schellings D; Slingeland Ziekenhuis, Doetinchem, the Netherlands., Lee MY; Long Beach Medical Center, Long Beach, California, USA., Kowey PR; Lankenau Heart Institute, Wynnewood, Pennsylvania, USA., Crijns HJGM; Maastricht University Medical Center (MUMC), Maastricht, the Netherlands., Maupas J; InCarda Therapeutics, Newark, California, USA., Belardinelli L; InCarda Therapeutics, Newark, California, USA.

Publikováno v: JACC. Clinical electrophysiology [JACC Clin Electrophysiol] 2024 Jun; Vol. 10 (6), pp. 1021-1033. Date of Electronic Publication: 2024 Apr 10.

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The VLT-FLAMES Tarantula Survey

Autor: N. J. Grin, O. H. Ramírez-Agudelo, A. de Koter, H. Sana, J. Puls, I. Brott, P. A. Crowther, P. L. Dufton, C. J. Evans, G. Gräfener, A. Herrero, N. Langer, D. J. Lennon, J. Th. van Loon, N. Markova, S. E. de Mink, F. Najarro, F. R. N. Schneider, W. D. Taylor, F. Tramper, J. S. Vink, N. R. Walborn

Publikováno v: Astronomy & Astrophysics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=r3c4b2081b22::837601ed470166ac6a794ea7f3308c1d

Zobrazit plný text záznamu

Akademický článek

Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial.

Autor: Abraham WT; Ohio State University Medical Center, Columbus, Ohio., Piccini JP; Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina., Dufton C; ARCA biopharma, Inc, Westminster, Colorado., Carroll IA; ARCA biopharma, Inc, Westminster, Colorado., Healey JS; Population Health Research Institute, McMaster University, Hamilton, California., O'Connor CM; Inova Heart and Vascular Institute, Fairfax, Virginia., Marshall D; ARCA biopharma, Inc, Westminster, Colorado., Aleong R; University of Colorado Anschutz Medical Campus Division of Cardiology, Aurora, Colorado., van Veldhuisen DJ; University of Groningen, University Medical Center, Groningen, the Netherlands., Rienstra M; University of Groningen, University Medical Center, Groningen, the Netherlands., Wilton SB; Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada., White M; Montreal Heart Institute, Montreal, Canada., Sauer WH; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Anand IS; University of Minnesota, Minneapolis, Minnesota., Huebler SP; ARCA biopharma, Inc, Westminster, Colorado., Connolly SJ; Population Health Research Institute, McMaster University, Hamilton, California., Bristow MR; ARCA biopharma, Inc, Westminster, Colorado.; University of Colorado Anschutz Medical Campus Division of Cardiology, Aurora, Colorado.

Publikováno v: Heart rhythm O2 [Heart Rhythm O2] 2021 Nov 14; Vol. 3 (1), pp. 40-49. Date of Electronic Publication: 2021 Nov 14 (Print Publication: 2022).

Zobrazit plný text záznamu

Akademický článek

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype.

Autor: Piccini JP; Duke Clinical Research Institute & Duke University Medical Center, Durham, NC (J.P.P.)., Dufton C; ARCA biopharma, Inc, Westminster, CO (C.D., I.A.C., D.M., M.R.B.)., Carroll IA; ARCA biopharma, Inc, Westminster, CO (C.D., I.A.C., D.M., M.R.B.)., Healey JS; Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., S.J.C.)., Abraham WT; Ohio State University Medical Center, Columbus (W.T.A.)., Khaykin Y; Southlake Regional Health Center, Newmarket, ON (Y.K.)., Aleong R; University of Colorado, Aurora (R.A., M.R.B.)., Krueger SK; Nebraska Heart Institute, Lincoln (S.K.K.)., Sauer WH; Brigham and Women's Hospital & Harvard Medical School, Boston, MA (W.H.S.)., Wilton SB; Libin Cardiovascular Institute of Alberta, University of Calgary (S.B.W.)., Rienstra M; University of Groningen & University Medical Center Groningen, the Netherlands (M.R., D.J.v.V.)., van Veldhuisen DJ; University of Groningen & University Medical Center Groningen, the Netherlands (M.R., D.J.v.V.)., Anand IS; University of Minnesota, Minneapolis (I.S.A.)., White M; Montreal Heart Institute, QC (M.W.)., Camm AJ; St. George's University of London, United Kingdom (A.J.C.)., Ziegler PD; Medtronic, PLC, Minneapolis, MN (P.D.Z.)., Marshall D; ARCA biopharma, Inc, Westminster, CO (C.D., I.A.C., D.M., M.R.B.)., Bristow MR; ARCA biopharma, Inc, Westminster, CO (C.D., I.A.C., D.M., M.R.B.).; University of Colorado, Aurora (R.A., M.R.B.)., Connolly SJ; Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., S.J.C.).

Publikováno v: Circulation. Arrhythmia and electrophysiology [Circ Arrhythm Electrophysiol] 2021 Aug; Vol. 14 (8), pp. e009591. Date of Electronic Publication: 2021 Jul 16.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání